To ask His Majesty's Government what assessment they have made of the impact of changes to the rebate in the Voluntary Scheme for Branded Medicines Pricing and Access, and to the accompanying Statutory Scheme, on (1) foreign direct investment into the UK Research and Development, (2) employment levels in the life sciences industry in the UK, and (3) medicines launches in the UK.
Answered on
7 February 2023
An impact assessment was published in December 2022 as part of the consultation on the impact of changes to the statutory scheme for branded medicines. The Department has received materials from pharmaceutical industry Trade Associations and from individual companies about a wide range of issues relevant to both the voluntary and statutory schemes for branded medicines pricing. We will be considering this evidence over the coming weeks and will publish our response alongside the final impact assessment.